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ABSTRACT (200 words) 
 
Purpose of review: This article reviews adult presentations of the major congenital 
myopathies - Central Core Disease (CCD), Multi-minicore Disease (MmD), Centronuclear 
Myopathy (CNM) and Nemaline Myopathy (NM) - , with an emphasis on common genetic 
backgrounds, typical clinico-pathological features and differential diagnosis. 
Recent findings: The congenital myopathies are a genetically heterogeneous group of 
conditions with characteristic histopathological features. Whilst essentially considered 
Paediatric conditions, some forms – in particular those due to dominant mutations in the 
skeletal muscle ryanodine receptor (RYR1), the dynamin 2 (DNM2), the amphiphysin 2 
(BIN1) and the Kelch Repeat-and BTB/POZ Domain-Containing Protein 13 (KBTBD13) gene 
– may present late into adulthood. Moreover, dominant RYR1 mutations associated with the 
malignant hyperthermia susceptibility (MHS) trait have been recently identified as a common 
cause of (exertional) rhabdomyolysis presenting throughout life. In addition, improved 
standards of care and development of new therapies will result in an increasing number of 
patients with early-onset presentations transitioning to the adult neuromuscular clinic. Lastly, 
if nemaline rods are the predominant histopathological feature, acquired treatable conditions 
have to be considered in the differential diagnosis.  
Summary: Recently identified genotypes and phenotypes indicate a spectrum of the 
congenital myopathies extending into late adulthood, with important implications for clinical 
practice. 
 
KEY WORDS: (5 key words) 
Congenital myopathies; adult presentations; skeletal muscle ryanodine receptor (RYR1) gene; 
exertional rhabdomyolysis; late-onset axial myopathy 
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INTRODUCTION (Total word count main text – 2485 words) 
 
The major congenital myopathies - Central Core Disease (CCD), Multi-minicore Disease 
(MmD), Centronuclear Myopathy (CNM), and Nemaline Myopathy (NM) – are a clinically 
and genetically heterogeneous group of neuromuscular disorders with characteristic but not 
always specific histopathological features (for review, [1]). 
Common clinical features include pronounced truncal and proximal weakness, and although 
it is often not possible to make a tentative diagnosis on clinical grounds alone, for example 
additional extraocular, distal or respiratory muscle involvement may provide important clues 
as to the underlying genetic defect (Table 1). Orthopaedic manifestations including scoliosis 
or ligamentous laxity are common. Although severity is highly variable, many of these 
conditions remain stable or are only slowly progressive over prolonged periods.  
Mutations in more than 15 genes have been implicated to date, encoding proteins with 
(putative) roles in calcium homeostasis and excitation-contraction coupling (ECC), thin and 
thick filament assembly and interaction, and membrane trafficking. Mutations in the skeletal 
muscle ryanodine receptor (RYR1) gene encoding RyR1, the principal sarcoplasmic reticulum 
(SR) calcium release channel, have been implicated to variable degrees in all major forms. In 
contrast to the congenital muscular dystrophies, integrity of the muscle cell is usually 
preserved, reflected in normal or only slightly elevated CK levels. Considering the 
complexities of the underlying genetics and clinical presentations, a coordinated 
multidisciplinary approach is essential [2, 3].    
The congenital myopathies are often considered pre-eminently Paediatric conditions, and 
many adult neurologists may feel uncomfortable with their diagnosis and management. 
However, not all congenital myopathies are of early onset and may indeed present only in 
adulthood. Moreover, improvements in supportive care and development of novel therapies 
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are likely to substantially reduce morbidity and mortality, resulting in an increasing number 
of patients with early-onset myopathies transitioning to adult neuromuscular services [4]. 
Lastly, the RYR1 gene has recently also been implicated in induced and episodic phenotypes 
such as (exertional) rhabdomyolysis (ERM) or periodic paralysis presenting throughout life. 
To highlight the relevance of the congenital myopathies for adult neuromuscular practice, this 
review will give an overview over the major entities, with a particular emphasis on late-onset 
presentations and induced and episodic phenotypes.               
 
CONGENITAL MYOPATHIES WITH CORES – CENTRAL CORE DISEASE (CCD) 
AND MULTI-MINICORE DISEASE (MmD) 
 
The “core myopathies” (for review, [5]) are the most common form of congenital myopathy 
[6, 7] and are most commonly associated with mutations in RYR1. RYR1 mutations have 
recently emerged as the predominant genetic cause of non-dystrophic neuromuscular 
disorders, associated with dominantly inherited CCD [8, 9], and subgroups of recessively 
inherited MmD [10-12], CNM [13] and congenital fibre type disproportion (CFTD) [14]. The 
dominantly inherited Malignant Hyperthermia Susceptibility (MHS) trait (for review, [15]), a 
pharmacogenetic predisposition to severe and potentially life-threatening reactions in 
response to halogenated anaesthetics and muscle relaxants, is an allelic condition. 
Although more severe presentations have been reported [16], dominantly inherited RYR1-
related CCD (for review, [17]) (Figure 1E, Figure 2A) is characterized by mild to moderate 
proximal weakness pronounced in the hip girdle presenting from infancy or childhood. 
Orthopaedic manifestations such as congenital hip dislocation, scoliosis and generalized joint 
hypermobility are common. In contrast to recessive RYR1-related myopathies, extraocular 
muscle (EOM) involvement is not a feature, and bulbar, respiratory and in particular cardiac 
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involvement is uncommon. Myalgia may be prominent [18]. Mild symptoms present from 
childhood may not have been recognized as such [19], resulting in often long intervals 
between initial symptom manifestation and eventual diagnosis. CCD tends to be stable over 
long periods with possible progression later in life [20]. Considering marked intrafamilial 
variability, the diagnosis of CCD in a patient should prompt a careful review of the family 
history and assessment of other relatives.            
RYR1-related MHS is allelic to CCD, and some patients with CCD may also be MH 
susceptible. Although the majority of MHS individuals are clinically asymptomatic unless 
exposed to potentially triggering agents, several permanent or induced neuromuscular 
manifestations appear to be specifically associated with MHS-related RYR1 mutations. King-
Denborough syndrome (KDS) [21], an early-onset myopathy with dysmorphic features, short 
stature, scoliosis and a predisposition to severe, occasionally unprovoked MH reactions, was 
recognized as a clinical entity by King and Denborough soon after their recognition of MHS 
[22]. More recently, (MHS-related) RYR1 mutations have also emerged as a common cause 
of (exertional) rhabdomyolysis (ERM) (Figure 1A-B), accounting for up to 30% of ERM 
presentations in otherwise healthy individuals after other causes have been excluded [23]. 
ERM can clearly be provoked by unaccustomed exercise even in individuals without genetic 
predisposition; however, a predisposing genetic background has to be considered if such 
episodes are familial, recurrent, out of context to the exercise performed, or preceded by 
other (exercise-induced) muscle symptoms such as cramps, myalgia and weakness. RYR1-
related rhabdomyolysis is commonly triggered by exercise, in particular in association with 
increased environmental temperatures, pyrexial illness, alcohol, medical or recreational 
drugs. Penetrance is low, with some individuals having had only one single episode despite 
an often intense exercise regime. In contrast to most metabolic causes, fasting does not 
appear to trigger RYR1-related rhabdomyolysis, and episodes may occur up to 72 hours after 
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exercise. RYR1-related rhabdomyolysis may mimick viral myositis [23, 24]. A recent case 
report indicates unaccustomed exercise before the triggering general anaesthesia as a 
contributory factor to MH [25], suggesting that MH may in fact be a multifactorial event and 
providing a potential explanation for its highly variable penetrance. Individuals with RYR1-
related rhabdomyolysis are often particularly muscular and athletic [23, 26], making life style 
advice after a rhabdomyolysis event more challenging. Dantrolene given around exercise or 
at the onset of symptoms (unlabeled use) may safely prevent or ameliorate episodes without 
significantly affecting performance [26]. Allopurinol has also recently been suggested as a 
treatment for exercise-induced muscle damage (unlabeled use) [27]. Late-onset axial 
myopathy [28, 29] (Figure 1C-D), characterized by often progressive paravertebral muscle 
weakness and wasting in previously athletic and muscular individuals, is another 
neuromuscular manifestation of MHS-related RYR1 mutations and shows clinical and genetic 
overlap with the ERM spectrum.      
Recessive RYR1-related MmD [11] (Figure 1F-H, Figure 2B) is usually of earlier onset 
compared to dominantly inherited CCD and often characterized by more pronounced 
weakness and EOM involvement. The condition tends to be stable over time and most 
patients will transition to the adult neuromuscular clinic. One case has been reported 
presenting with features of atypical periodic paralysis presenting from adolescence [30]. 
Recessive SEPN1-related MmD [31], the second most common form of core myopathy, 
usually presents in childhood with spinal rigidity, scoliosis and early respiratory failure 
typically requiring non-invasive ventilation by the second decade. In contrast to the RYR1-
related form, EOM involvement is not a typical feature. The condition tends to remain stable 
over prolonged periods, with marked discrepancy between profound respiratory impairment 
and often fully preserved ambulation.      
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Primary cardiomyopathies have been described in rarer forms of genetically distinct core 
myopathies. Amongst those, dominant mutations in MYH7 may present with the typical 
clinico-pathological features of MmD in childhood but then develop features of Laing Distal 
Myopathy, an allelic condition [32, 33]. Recessive mutations in the giant TTN gene have been 
implicated in severe core myopathies with cardiac involvement [34] and may often feature a 
mixed pathology with additional fibre type disproportion and multiple internalized nuclei (see 
below). Considering frequent features of spinal rigidity, scoliosis and multiple contractures 
also involving the elbows, both TTN- and MYH7-related forms of core myopathies may 
mimick Emery-Dreifuss Muscular Dystrophy (EDMD). There is also overlap with the 
myofibrillar myopathy (MFM) spectrum [35] and KBTBD13-related nemaline myopathy 
[36], which may feature cardiac involvement and additional cores on muscle biopsy (see 
below).      
 
CONGENITAL MYOPATHIES WITH CENTRAL NUCLEI – X-LINKED 
MYOTUBULAR MYOPATHY (XLMTM) AND CENTRONUCLEAR MYOPATHY 
(CNM) 
 
Centronuclear myopathies (CNMs) are characterized by the abundance of central nuclei on 
muscle biopsy (for review, [37, 38]). CNM has been associated with X-linked recessive 
mutations in MTM1 encoding myotubularin [“X-linked myotubular myopathy (XLMTM)”] 
[39], autosomal-dominant mutations in DNM2 encoding dynamin2 [40] and the BIN1 gene 
encoding amphiphysin 2 [41], and autosomal-recessive mutations in BIN1 [42], RYR1 
encoding the skeletal muscle ryanodine receptor [13], and TTN encoding titin [43]. Most 
genes implicated to date encode proteins implicated in membrane trafficking (for review, 
[44]).  
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Type 1 fibre predominance and atrophy are common histopathological features in all forms. 
In contrast to MTM1-, DNM2- and BIN1- related CNM, nuclei tend to be multiple 
internalized rather than strictly centralized in RYR1- and TTN-related CNM [13, 43]. 
Evolution of additional cores is particularly common in the RYR1-related form [45], and 
some patients may have marked fibre type disproportion [13]. A peculiar radial distribution 
of sarcoplasmic strands around central nuclei is a distinctive and consistent feature of DNM2-
related CNM [40, 46-50], but has also been described in mild cases with dominantly inherited 
BIN1-related CNM; the latter form may also feature nuclear clustering. “Necklace fibres” 
have been reported in mild cases of XLMTM [51] and DNM2-related CNM [52].  
XLMTM is the most common and the most severe form, with the majority of affected males 
not surviving beyond the first year of life unless fulltime ventilator support is provided [53]. 
However, a proportion may survive into adulthood without the need for longterm ventilation; 
the MTM1 p.Glu157Lys mutation has been associated with a particularly mild phenotype 
[54]. Some XLMTM carriers may develop mild weakness [55], sometimes very late in life 
[56], but more severe manifestations in females are usually due to skewed X-inactivation or 
additional X-chromosomal abnormalities [57, 58]. There is a wide range of animal models of 
XLMTM with similar muscle pathology, summarized in a recent review [59].  
Dominantly inherited DNM2-related CNM [40, 46, 60] is the form of CNM most likely to be 
encountered by an adult neurologist. Although more severe cases have been reported [46, 61], 
affected individuals typically present in adolescence or adulthood [60, 62-64], occasionally as 
late as the 6
th
 decade. Exertional myalgia may be a presenting feature. Facial weakness, ptosis 
and EOM involvement are common but not universal. Jaw contractures are a feature in some 
patients [49, 65]. Muscle weakness is mainly proximal and axial, with frequent additional 
distal involvement [66-68] and, occasionally, marked muscle hypertrophy, particularly 
affecting the calves [52, 69]. Respiratory involvement is a feature in more severely affected 
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infants and may improve over time [46, 50, 61, 65]. Dominant intermediate CMTDIB [70] 
and axonal CMTM [71] are allelic conditions, and, although DNM2 mutations implicated in 
CNM and CMT are distinct, there may be some clinical overlap in individual cases, as 
evidenced by frequently absent deep tendon reflexes and variable neurophysiological and 
neuropathological evidence for an associated mild neuropathy [49, 60, 64, 67, 68, 72]. An 
associated neuromuscular transmission defect and positive response to acetylcholinesterase 
inhibitors has been reported [73]. Additional multisystem involvement featuring neutropenia 
[52, 69] or cataracts [61, 74] has occasionally been observed. Muscle MRI may help to 
distinguish DNM2-related from other congenital myopathies [64, 66].  
Dominant mutations in BIN1, previously associated with rare, recessively inherited severe 
CNM cases [42], have also been recently associated with a mild dominant form of CNM [41] 
(Figure 2C). Patients typically present later in adulthood with proximal weakness pronounced 
in the lower limbs, without significant respiratory impairment and only rarely extraocular 
muscle involvement. Muscle MRI may show additional distal muscle involvement.  
RYR1-related CNM shares features with other recessive RYR1-related myopathies, in 
particular marked EOM involvement and a tendency to improve over time. EOM 
involvement is not a feature in TTN-related CNM; although cardiac involvement was not 
prominent in the original series [43], this ought to be monitored for considering the severe 
cardiac phenotypes in other TTN-related disorders.    
 
CONGENITAL MYOPATHIES WITH NEMALINE RODS – NEMALINE 
MYOPATHY (NM) 
 
Nemaline myopathy (NM) is one of the more common congenital myopathies and 
characterized by numerous nemaline rod bodies on muscle biopsy that appear red with the 
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Gömöri trichrome stain and are prominent in Toluidine Blue-stained semithin resin sections 
[for review, [75]]. To date, 10 genes have been linked to this disorder, including ACTA1, 
NEB, TPM3, TPM2, CFL2, TNNT1, LMOD3, KBTBD13, KLHL40, and KLHL41, of which 
recessive mutations in NEB and (de novo) dominant mutations in ACTA1 are the most 
common (for review, [75]). NM is associated with highly variable degrees of muscle 
weakness, ranging from presentations within the fetal akinesia spectrum to only mildly 
affected adults.  
NEB-related NM, the most common form, typically presents in infancy or childhood, often 
with disproportionate axial and bulbar involvement [76]. Scoliosis is common and respiratory 
involvement almost universal, despite preserved ambulation well into adulthood. Distal 
involvement in the lower limb becomes prominent over time and may be a presenting feature 
in some patients [77]. Although ACTA1-related NM is typically a profoundly severe 
condition [4, 78], rare patients may present in adulthood with respiratory failure but only little 
limb girdle weakness [79,80]. An associated cardiomyopathy is not a feature of NEB-related 
NM but has been rarely encountered in patients with ACTA1 mutations [81,82]. An ACTA1-
related progressive scapuloperoneal myopathy without nemaline rods on muscle biopsy [82] 
has been recently reported.  
The form of NM most relevant to adult practice is the recently identified form due to 
dominant mutations in the KBTBD13 gene (Figure 2D), or NEM6 [36] whose overall 
frequency is currently uncertain. NEM6 is characterized by a peculiar slowness of 
movements, and the development of slowly progressive muscle weakness affecting neck and 
proximal limb muscles. As in other adult-onset congenital myopathies, muscle weakness 
often manifests not until adolescence or adulthood, but all patients retrospectively report 
difficulties with sport in childhood [36, 84]. The characteristic slowness is often perceived as 
clumsiness, with patients generally unable to sprint or to suddenly adapt their position to 
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avoid falls. Respiratory insufficiency and cardiac abnormalities were not reported in the 
initial cohort [36] but have been observed in some patients since then (personal observation). 
Recently, muscle weakness was also confirmed at sarcomere level [85].   
Although all the defining features of the congenital myopathies may occur in different 
contexts, nemaline rods are probably the histopathological feature that has been most 
frequently associated with non-genetic causes, many of them manifesting in adulthood and 
summarily referred to as sporadic late-onset nemaline myopathy (SLONM). The most 
frequent acquired causes include monoclonal gammopathy, HIV, and various autoimmune 
disorders [86,87]. The most distinguishing feature compared to genetic forms of NM is the 
complete absence of weakness in childhood or adolescence, and the fast rate of progression, 
with patients developing severe limb girdle, axial and respiratory weakness in the course of a 
few years. Timely recognition is essential considering that SLONM is potentially treatable, 
and screening for M-protein and HIV infection should therefore be part of the diagnostic 
work-up in cases of rapidly progressive muscle weakness in adulthood.  
 
CONCLUSIONS 
 
Congenital myopathies with presentation in adolescence or adulthood are of relevance to 
adult (neuromuscular) neurologists. In addition, improved standards of care and development 
of new therapies will result in an increasing number of Paediatric patients transitioning to the 
adult neuromuscular clinic, emphasizing the need for robust natural history data beyond 
childhood. Mutations in RYR1, the most common cause of congenital myopathies, may also 
give rise to “induced” and episodic manifestations presenting throughout life. Non-genetic 
causes ought to be considered if histopathological features, in particular nemaline rods, are 
unexpected in the clinical context.  
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KEY POINTS 
 
Congenital myopathies may present in adulthood in particular if associated with dominant 
mutations in the skeletal muscle ryanodine receptor (RYR1), the dynamin 2 (DNM2), the 
amphiphysin 2 (BIN1) and the Kelch Repeat-and BTB/POZ Domain-Containing Protein 13 
(KBTBD13) gene. 
 
Exertional rhabdomyolysis and late-onset axial myopathy are two manifestations of dominant 
RYR1 mutations particularly relevant to adult neuromuscular practice that may also be 
associated with the malignant hyperthermia susceptibility (MHS) trait. 
 
Reflective of improved standards of care and the advent of novel therapies, an increasing 
number of patients with early-onset congenital myopathies will transition to the adult 
neuromuscular clinic in future.  
 
Non-genetic causes have to be considered if histopathological features, in particular nemaline 
rods, are unexpected in the clinical context.    
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* Series of clinical features and treatment response in 8 patients with sporadic late-onset 
nemaline myopathy (SLONM) associated with monoclonal gammopathy of unknown 
significance (MGUS).  
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FIGURE AND TABLES 
 
Figure 1  
The clinical spectrum of RYR1-related myopathies presenting in adulthood. A) 17-year-
old male presenting with recurrent exertional rhabdomyolysis (ERM) associated with a 
paternally inherited heterozygous RYR1 mutation putatively associated with Malignant 
Hyperthermia (MH) (reported in [26]). Note mild ptosis, often the only myopathic sign in 
patients presenting with RYR1-related ERM, and B) subtle scapular winging.  C-D) Two 47-
year-old patients (reported in [19, 29] with late-onset axial myopathy due dominant RYR1 
mutations. Note scapular winging and wasting of the paravertebral muscles. Although much 
more pronounced, these findings are similar to those shown in B), indicating a continuum 
between the RYR1-related ERM and late-onset axial myopathy spectrum. E) 60-year-old 
patient with dominantly inherited RYR1-related CCD (reported in [19]), showing exaggerated 
lumbar lordosis, mild scoliosis and tendon Achilles tightness. F-H) 35-year-old patient with 
RYR1-related MmD with ophthalmoparesis (reported in [19]). Note marked limitation of 
extraocular movements, pronounced on attempted upward gaze (G) and, to a lesser extent, 
abduction and adduction (F,H).           
 
Figure 2  
Histopathological features of congenital myopathies presenting in adulthood. A) Muscle 
biopsy from 60-year-old male (shown in Figure 1E) with a dominantly inherited, RYR1-
related core myopathy (CCD). On SDH stain (transverse sections) there are predominantly 
well-defined central cores, but also additional smaller, more irregular and occasionally 
confluent core structures. B) Muscle biopsy from a 50-year-old male with a recessively 
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inherited, RYR1-related core myopathy (MmD). On SDH stain (transverse sections) there are 
multiple small cores in many fibres, often in an eccentric position. 
C)  Muscle biopsy from a 63-year-old female with dominantly inherited, BIN1-related CNM. 
Note increase in central nuclei on H&E stain, transverse sections. D) Muscle biopsy from 36-
year-old female with dominantly inherited KBTBD13-related NM. There are numerous 
nemaline rods appearing red on the Gomöri trichome stain, transverse sections. Rods were 
also prominent on Toluidine Blue-stained semithin resin sections (data not shown).  
 
Table 1  
Clinical and histopathological clues to a specific diagnosis in congenital myopathies in 
adults. Please note that many of the indicated features may also occur in other congenital 
myopathies and with different genetic backgrounds, although at lower frequency.  CMS = 
Congenital Myasthenic Syndromes; DM1 = Myotonic Dystrophy Type 1; EDMD = Emery-
Dreifuss Muscular Dystrophy; FSHD – Facioscapulohumeral Muscular Dystrophy; MFM = 
Myofibrillar Myopathy; SLONM = Sporadic Late Onset Nemaline Myopathy   
 
 
 
 
 
 
 
 
 
 
27 
 
 
 
Figure 1 
 
 
 
 
 
 
 
 
 
28 
 
 
Figure 2 
 
 
 
 
 
 
 
 
 
 
29 
 
Feature  Congenital myopathy Genes Differential diagnosis 
     
Clinical feature     
     
Childhood onset  CCD, MmD, NM, 
CNM  
RYR1 (AR>AD), NEB, ACTA1, MTM1 (milder cases), 
DNM2 
CMS, DM1, mitochondrial conditions 
Adult onset  CCD, CNM, NM RYR1 (AD>AR), DNM2, BIN1 (AD), KBTD13  DM1, mitochondrial conditions 
     
Facial weakness  MmD, CNM, NM RYR1 (AR), DNM2, NEB DM1, CMS, mitochondrial conditions, FSHD 
Ptosis  CNM, MmD, CCD DNM2, RYR1 DM1, CMS, mitochondrial conditions 
EOM  MmD, CNM RYR1 (AR), DNM2, MTM1(mild cases, manifesting carriers)  CMS, mitochondrial conditions 
     
Scoliosis   MmD, CNM, NM SEPN1, RYR1, NEB   COL6-related myopathies, MFM 
Rigid spine  MmD, NM SEPN1, MYH7, TTN, NEB COL6-related myopathies, EDMD, MFM 
     
Distal weakness lower 
limbs 
 NM, CNM, MmD NEB, DNM2, MYH7 Peripheral neuropathy 
Pes cavus  CNM DNM2 Peripheral neuropathy 
     
Bulbar weakness  NM, MmD NEB, RYR1 (AR) CMS, DM1, mitochondrial conditions 
Respiratory impairment  MmD, NM, CNM SEPN1, NEB, ACTA1, DNM2 Acid maltase deficiency, mitochondrial 
conditions 
Cardiac involvement  MmD, NM TTN, MYH7, (ACTA1), (KBTBD13) EDMD, mitochondrial conditions, MFM 
     
Neuropathy  CNM DNM2 Peripheral neuropathy, MFM 
     
Malignant hyperthermia  CCD, MmD RYR1 Other causes of MH 
     
Histopathology      
     
Central cores  CCD RYR1 Target fibres 
Multi-minicores  MmD SEPN1, RYR1 (AR), TTN (± internal nuclei), MYH7 COL6-related myopathies, MFM 
Central nuclei  CNM DNM2, BIN1, RYR1 (AR) (multiple internal), TTN (± cores) DM1 
- radial strands  CNM DNM2, (BIN1)  
- necklace fibres  CNM MTM1 (mild cases, manifesting carriers), DNM2  
Nemaline rods  NM KBTBD13 (± cores) SLONM 
     
Table 1 
